Earnest Partners LLC lowered its stake in Catalent Inc (NYSE:CTLT) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,498,774 shares of the company’s stock after selling 71,382 shares during the period. Catalent accounts for 1.0% of Earnest Partners LLC’s portfolio, making the stock its 28th largest position. Earnest Partners LLC owned 1.87% of Catalent worth $102,650,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently modified their holdings of CTLT. Nationwide Fund Advisors grew its holdings in Catalent by 18.4% during the 3rd quarter. Nationwide Fund Advisors now owns 382,620 shares of the company’s stock worth $15,274,000 after acquiring an additional 59,528 shares during the period. First Trust Advisors LP grew its holdings in Catalent by 1.5% during the 3rd quarter. First Trust Advisors LP now owns 109,815 shares of the company’s stock worth $4,384,000 after acquiring an additional 1,597 shares during the period. Aperio Group LLC grew its holdings in Catalent by 9.8% during the 3rd quarter. Aperio Group LLC now owns 25,362 shares of the company’s stock worth $1,012,000 after acquiring an additional 2,274 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in Catalent during the 3rd quarter worth $451,000. Finally, Victory Capital Management Inc. acquired a new stake in Catalent during the 3rd quarter worth $1,182,000. 99.89% of the stock is owned by institutional investors and hedge funds.
A number of research firms have commented on CTLT. Goldman Sachs Group began coverage on shares of Catalent in a report on Wednesday, January 24th. They set a “buy” rating and a $50.00 target price for the company. Royal Bank of Canada set a $48.00 target price on shares of Catalent and gave the stock a “buy” rating in a report on Monday, February 5th. Stephens lowered shares of Catalent from an “overweight” rating to an “equal weight” rating in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a report on Wednesday, January 17th. Finally, Bank of America boosted their price target on shares of Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a report on Tuesday, February 6th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $45.40.
Catalent Inc (NYSE CTLT) opened at $42.93 on Monday. Catalent Inc has a fifty-two week low of $27.48 and a fifty-two week high of $47.87. The stock has a market cap of $5,723.37, a price-to-earnings ratio of 26.83, a PEG ratio of 2.46 and a beta of 1.54. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm’s revenue was up 25.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.27 EPS. sell-side analysts expect that Catalent Inc will post 1.53 earnings per share for the current fiscal year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.